Windtree Therapeutics (NASDAQ:WINT) Shares Scheduled to Reverse Split on Monday, April 22nd

Windtree Therapeutics, Inc. (NASDAQ:WINT)’s stock is going to reverse split on Monday, April 22nd. The 1-18 reverse split was announced on Monday, April 22nd. The number of shares owned by shareholders will be adjusted after the market closes on Monday, April 22nd.

Windtree Therapeutics Trading Down 15.3 %

WINT traded down $0.06 during trading hours on Thursday, reaching $0.34. 1,789,008 shares of the company’s stock traded hands, compared to its average volume of 280,849. The firm has a 50-day moving average price of $0.37 and a 200 day moving average price of $0.67. Windtree Therapeutics has a 52-week low of $0.27 and a 52-week high of $7.79. The company has a quick ratio of 2.40, a current ratio of 2.40 and a debt-to-equity ratio of 2.00. The firm has a market capitalization of $1.75 million, a PE ratio of -0.04 and a beta of 0.61.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “neutral” rating on shares of Windtree Therapeutics in a report on Wednesday, January 3rd.

Hedge Funds Weigh In On Windtree Therapeutics

A number of large investors have recently bought and sold shares of WINT. Renaissance Technologies LLC boosted its holdings in Windtree Therapeutics by 8.8% during the 1st quarter. Renaissance Technologies LLC now owns 234,446 shares of the company’s stock valued at $267,000 after acquiring an additional 18,946 shares during the period. Millennium Management LLC lifted its holdings in shares of Windtree Therapeutics by 411.1% in the 2nd quarter. Millennium Management LLC now owns 79,858 shares of the company’s stock worth $33,000 after buying an additional 64,232 shares during the period. Envestnet Asset Management Inc. lifted its holdings in shares of Windtree Therapeutics by 894.7% in the 3rd quarter. Envestnet Asset Management Inc. now owns 107,302 shares of the company’s stock worth $32,000 after buying an additional 96,515 shares during the period. Citadel Advisors LLC purchased a new stake in shares of Windtree Therapeutics in the 2nd quarter worth $27,000. Finally, Vanguard Group Inc. purchased a new stake in shares of Windtree Therapeutics in the 3rd quarter worth $40,000. Hedge funds and other institutional investors own 29.33% of the company’s stock.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure.